crizanlizumab,voxelotor
global blood therapeutics,novartis
['voxelotor', 'crizanlizumab']
looking over time, by 2021, about 35% of their population had used any one of the dmts. this is still low! only a third! more use of voxelotor and crizanlizumab after approval but still &lt;5% of population use these. #ash22 5/5
Peds hem/onc enthusiast with interest in med ed (former PD @ UCSF), QI & safety, hemostasis/thrombosis. Former Saipan pediatrician. Tweets are my own